Our internationally recognised publications give you access to the expertise of hundreds of the world’s leading scientists, experts and researchers.

Our unrivalled collection of publications spans evidence-based clinical knowledge, research and regulatory information. The extensive breadth of content on MedicinesComplete supports your decision making, from research to the point of care and provides you with the world’s most trusted resources.

We’re excited to announce the launch of two new resources: Martindale’s ADR Checker, a quick and easy tool to support you when managing patients with adverse drug reactions, and the Palliative Care Formulary, the expert source of drug information in palliative and hospice care.

Subscribe Publication Updates

Publication Updates

14 May
Stockley's Interactions Checker_logo
Stockley’s Interaction Checker May 2019 Update

New and updated interactions now available

For May, 405 new interactions have been added, and 913 existing interactions have been updated.

14 May
Pharmaceutical Excipients logo
Pharmaceutical Excipients May 2019 update

This update contains 52 updated monographs, 2 new Chapters, over 50 new chemical structure graphics and the revalidation of the Regulatory status of over 50 Excipient monographs. The British Pharmacopoeia, European Pharmacopoeia, and USP-NF information has been globally updated.

New Chapters: Biological Effects of Pharmaceutical Excipients and The Selection of Excipients for Injectable Formulations.

Minor Updates: Acetone, Adipic Acid, Aluminum Hydroxide Adjuvant, Aluminum Phosphate Adjuvant, Ascorbyl Palmitate, Boric Acid, Calcium Carbonate, Calcium Lactate, Calcium Phosphate Tribasic, Cellulose Acetate, Cellulose Acetate Phthalate, Cellulose Microcrystalline, Citric Acid, Diethanolamine, Docusate Sodium, Erythritol, Gluconolactone, HydrochloricAcid, Hydroxyethylpiperazine Ethane Sulfonic Acid, Isopropyl Isostearate, Isopropyl Myristate, Lactic Acid, Lauric Acid, Lecithin, Magnesium Carbonate, Malic Acid, Meglumine, Octyl Gallate, Paraffin, Peanut Oil, Phenylethyl Alcohol, Phenylmercuric Acetate, Phenylmercuric Borate, Phenylmercuric Nitrate, Phospholipids, Potassium Alum, Potassium Chloride, Potassium Metaphosphate, Potassium Nitrate, Pyrrolidone, Simethicone, Sodium Borate, Sodium Chloride, Sodium Citrate Dihydrate, Sodium Hydroxide, Sodium Phosphate Dibasic, Sodium Propionate, Soybean Oil, Starch Pregelatinized, Stearyl Alcohol, Sucrose Palmitate, Sugar Confectioner’s.

14 May
Stockleys Drug Interactions_logo
Stockley’s Drug Interactions May 2019 Update

Stockley’s Drug Interactions update with new and revised monographs.

For this update, several sections have been completely re-validated and updated, including those on abiraterone, the cannabinoids, and methotrexate. New drugs that have been added include lorcaserin, pimavanserin, pitolisant, telotristat ethyl, and tezacaftor. This update contains 42 new monographs, and 149 existing monographs have been updated.

14 May
Dietary Supplements logo
Dietary Supplements May 2019 Update

This update contains revisions to 5-HTP, Acai, Acerola, Aloe Vera, Alpha-lipoic Acid and Androstenedione monographs.

14 May
British National Formulary logo
BNF May 2019 Update

This update contains 11 significant changes, 1 dose changes and 5 new preparations.

Significant Changes:   

  • Benralizumab for treating severe eosinophilic asthma [NICE guidance].
  • Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib [NICE guidance].
  • Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes [NICE guidance].
  • Fluoroquinolone antibiotics (ciprofloxacin): new restrictions and precautions for use due to very rare reports of disabling and potentially long-lasting or irreversible side effects [MHRA/CHM advice].
  • Fluoroquinolone antibiotics (levofloxacin, moxifloxacin, ofloxacin): new restrictions and precautions for use due to very rare reports of disabling and potentially long-lasting or irreversible side effects [MHRA/CHM advice].
  • Irinotecan hydrochloride, liposomal formulations (Onivyde®): reports of serious and fatal thromboembolic events [MHRA/CHM advice].
  • Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer [NICE guidance].
  • Pneumococcal vaccine: updated guidance in-line with Public Health England recommendations.
  • Prescribing in pregnancy: medicines with teratogenic potential: what is effective contraception and how often is pregnancy testing needed? [MHRA/CHM advice].
  • Respiratory system infections, antibacterial therapy: new guidance for acute exacerbations of Bronchiectasis (non-cystic fibrosis
  • Respiratory system infections, antibacterial therapy: updated guidance for acute exacerbations of Chronic obstructive pulmonary disease.

Dose Changes:

  • Alirocumab [Dosing options for Primary hypercholesterolaemia or mixed dyslipidaemia].

New Preparations: Buvidal® [buprenorphine], Erleada® [apalutamide], Fortacin® [lidocaine with prilocaine], Symkevi® [tezacaftor with ivacaftor], Tegsedi® [inotersen].

For further details on changes in the BNF click on http://www.medicinescomplete.com/mc/bnf/current/PHP107699-changes.htm

14 May
AHFS Drug Information logo
AHFS May 2019 Update

This update contains 3 new monographs, 31 revised monographs and 1 new MedWatch alerts.

New monographs: Triclabendazole, Esketamine Hydrochloride, Cetirizine Hydrochloride

Revised monographs: Fondaparinux, Palonosetron, OnabotulinumtoxinA, guanFACINE, Tofacitinib, Mechlorethamine, AbobotulinumtoxinA, IncobotulinumtoxinA, RimabotulinumtoxinB, Mepolizumab, Netupitant/Palonosetron, Obeticholic Acid, Netarsudil, Ibalizumab-uiyk, Erenumab-aooe,
Fremanezumab-vfrm, Galcanezumab-gnlm, aMILoride, Methyldopa, Chlorothiazide, Nystatin, Potassium Supplements, Ethacrynic Acid, Felodipine, Fosinopril, Quinapril, Torsemide, Moexipril, Nisoldipine, Trandolapril, Perindopril

New MedWatch alerts on the following monographs: Febuxostat

View more